Evidence map›Paper›PMID 40030035›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2025

The NAE1-mediated neddylation operates as an essential post-translational modification checkpoint for effector CD8

Jiacheng Jin, Ruohan Zhang, Jianying Li, Fengxia Gao, Zhiwei Liao, Yanbao Yu, Yi Wang, Donna Bucci, Min Xiao, Ruilin Ma and 11 more

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Post-Translational Regulation of CD8Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  3. Post-translational modifications in CD8Frontiers in immunology · 2026
    Review
  4. Review
  5. The NAE1-mediated neddylation operates as an essential post-translational modification checkpoint for effector CD8Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Jiacheng Jin *Pelotonia Institute for Immuno-oncology, Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, College of Medicine, The Ohio State University, Columbus, OH 43210.
Ruohan ZhangDepartment of Physiology and Cell Biology, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH 43210.
Jianying Li *Pelotonia Institute for Immuno-oncology, Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, College of Medicine, The Ohio State University, Columbus, OH 43210.
Fengxia GaoPelotonia Institute for Immuno-oncology, Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, College of Medicine, The Ohio State University, Columbus, OH 43210.
Zhiwei LiaoPelotonia Institute for Immuno-oncology, Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, College of Medicine, The Ohio State University, Columbus, OH 43210.
Yanbao YuDepartment of Chemistry and Biochemistry, Mass Spectrometry Facility, University of Delaware, Newark, DE 19716.
Yi WangPelotonia Institute for Immuno-oncology, Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, College of Medicine, The Ohio State University, Columbus, OH 43210.
Donna BucciPelotonia Institute for Immuno-oncology, Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, College of Medicine, The Ohio State University, Columbus, OH 43210.
Min XiaoPelotonia Institute for Immuno-oncology, Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, College of Medicine, The Ohio State University, Columbus, OH 43210.
Ruilin MaDepartment of Chemistry, New York University, New York, NY 10003.
Qin MaPelotonia Institute for Immuno-oncology, Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, College of Medicine, The Ohio State University, Columbus, OH 43210.
Shuaixin GaoDepartment of Human Sciences, College of Education and Human Ecology, The Ohio State University, Columbus, OH 43210.
Jerry LioDepartment of Microbial Infection and Immunity, The Ohio State University College of Medicine, Columbus, OH 43210.
Fernanda NovaisDepartment of Microbial Infection and Immunity, The Ohio State University College of Medicine, Columbus, OH 43210.
Stanley Ching-Cheng HuangPelotonia Institute for Immuno-oncology, Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, College of Medicine, The Ohio State University, Columbus, OH 43210.
Jiangjiang ZhuDepartment of Human Sciences, College of Education and Human Ecology, The Ohio State University, Columbus, OH 43210.
Hazem GhoneimPelotonia Institute for Immuno-oncology, Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, College of Medicine, The Ohio State University, Columbus, OH 43210.
Haitao WenPelotonia Institute for Immuno-oncology, Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, College of Medicine, The Ohio State University, Columbus, OH 43210.ORCID 0000-0002-6363-2748
Zihai LiPelotonia Institute for Immuno-oncology, Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, College of Medicine, The Ohio State University, Columbus, OH 43210.ORCID 0000-0003-4603-927X
Nuo SunDepartment of Physiology and Cell Biology, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH 43210.
Gang XinPelotonia Institute for Immuno-oncology, Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, College of Medicine, The Ohio State University, Columbus, OH 43210.

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Daniel G. Stover · 1985 to 2026
$132.3M
Neddylation and mitophagy in cardiac agingR01HL162909 · NHLBI · OHIO STATE UNIVERSITY · PI Nuo Sun · 2022 to 2026
$3.0M
Distinct functions for CD8 T cells in cutaneous leishmaniasisR01AI162711 · NIAID · OHIO STATE UNIVERSITY · PI Fernanda Novais · 2022 to 2026
$2.1M
Targeting GPR84 to Overcome Macrophage Mediated Resistance to ImmunotherapyR01CA269984 · NCI · OHIO STATE UNIVERSITY · PI Gang Xin · 2023 to 2026
$1.4M
American Cancer Society (ACS) RSG-23-1036499-01HHS | NIH | National Cancer Institute (NCI) 1R01CA269984NCI NIH HHS P30 CA016058NCI NIH HHS R01 CA269984NHLBI NIH HHS R01 HL162909NIAID NIH HHS R01 AI162711Susan G. Komen (SGK) CCR231013713
6 · The paper itself

Abstract

Optimal activation of CD8+ T cells is crucial for immunity-mediated destruction of cancer, requiring a substantial amount of proteins involved in metabolism, proliferation, and effector function. Despite extensive studies emphasizing the role of transcriptional regulation in this process, paired transcriptomic and proteomic analyses reveal that the RNA profile is poorly correlated with protein levels. This discrepancy underscores the importance of post-translational modifications (PTMs) in controlling protein abundance during activation. However, the impact of PTMs on the CD8+ T cell protein dynamic remains underexplored. We identify that neddylation, a recently discovered PTM, is activated in response to T cell receptor (TCR) stimulation and enriched in effector CD8+ T cells from colon cancer patients. Mechanistically, we found the rate-limiting enzyme of neddylation, neural precursor cell expressed developmentally down-regulated protein 8 activating enzyme E1 (NAE1), is induced by the NFATc1, a critical transcription factor downstream of TCR signaling. Our observation revealed that genetic ablation of NAE1 significantly disturbed the proteomic landscape related to activation and mitochondrial function. As a result, CD8+ T cells lacking NAE1 exhibited severely compromised activation, proliferation, and survival, which was accompanied by impaired mitochondrial function. Consistently, deletion of NAE1 in CD8+ T cells abolished their antitumor function and promoted tumor progression. By contrast, the overexpression of NAE1 significantly improved the function of tumor-infiltrating CD8+ T cells. Overall, we uncovered neddylation, a previously underappreciated PTM, as a proteomic checkpoint for CD8+ T cell activation. Enforced expression of NAE1 offers promising therapeutic potential for boosting the antitumor CD8+ T cell responses.

Indexed as

CD8-Positive T-LymphocytesNEDD8 ProteinProtein Processing, Post-TranslationalUbiquitin-Activating EnzymesAnimalsColonic NeoplasmsHumansLymphocyte ActivationMiceMice, Inbred C57BLNFATC Transcription FactorsProteomicsReceptors, Antigen, T-CellNEDD8 ProteinNFATC Transcription FactorsReceptors, Antigen, T-CellUbiquitin-Activating Enzymesimmunotherapypost-translational modificationsT cells

Identifiers

PMID40030035
PMCPMC11912420

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.